NanoViricides, Inc. Announces New Herpes Keratitis Study
On Monday May 11, 2009, 7:00 am EDT
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that it has signed a pre-clinical study agreement for the evaluation of NanoViricides’ drug candidate for herpes keratitis of the eye. The study will be conducted by Thevac, LLC, a spin-off of the Louisiana State University (LSU), Baton Rouge, LA. It will be performed in collaboration with the Division of Biotechnology and Molecular Medicine at the LSU School of Veterinary Medicine, which administers the LSU-Tulane Center for Experimental Infectious Disease Research (Director, K. G. Kousoulas, PhD).
Herpes keratitis (herpes virus infection of the cornea) is a serious, potentially blinding disease of the eye. It is the leading infectious cause of blindness in developed countries and the most common infectious corneal disease in the United States. It can often necessitate corneal transplantation. Herpes virus infections and adenoviral infections of the cornea together constitute most of the viral disease of the external eye. At present, there is no satisfactory treatment that works for both adenoviral and herpesvirus keratitis/conjunctivitis. The potential domestic market for a drug effective against all or most viral infections of the external eye is variously estimated to be from $500M to billions of dollars.
“We are very pleased to have a recognized expert like Dr. Kousoulas associated with this study,” said Eugene Seymour, MD, MPH, Chief Executive Officer of NanoViricides, Inc., adding, “This will provide us with independent results for the nanoviricide™ drug candidates against viral diseases of the external eye. Separate studies are expected to begin shortly in collaboration with a pharmaceutical company.”
“The NanoViricides technology appears to be very promising for treating a variety of viral diseases including influenza,” says Dr. Kousoulas.
About THEVAC, LLC
THEVAC, LLC is a LSU spin-of company, which has been formed to produce valuable reagents and provide sophisticated services to industry in collaboration with LSU Baton Rouge.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
18 comments:
NNVC keeps fishing, they're bound to catch something sooner than later...though sooner would be nice. I like how much overlap their technology offers with regard to other viruses, would really seem like a cure-all (for viruses) once it's fully understood, developed, and accepted.
Eric,
This one drug (out of 6-8 drugs) is addressing a market the size of "$500K to many billions". No competition insofar as no other effective treatments on the market. We know from past PR's that NNVC's drug is effective. How many $Billions is this company going to be worth in a few years? Right now, it's market cap is less then 10% of One Billion. Thus minimum valuation could be 100 X current price FOR STARTERS!
10K shares = $1M in 5 years may be gross understatement.
just to get things correct:
"$500mn to many billions"
:)
Thanks, alfaomega, broke my own rule about posting comments before coffee.
Despite some recent positive news, share price moves in a vicious circle - nonetheless this has to be broken sometimes in the future, and the title deserves enough patience - reward should be sufficient :)
This is all pre-clinical. What plans does NNVC have to get these drugs into trials? For the years I've been reading about this company here, it's been a lot of talk and zero results.
Allan:
what happened if some big pharma realize NNVC's potential and decide to buy them out ... even paying 100% premium, we will only get $1.50 a share ...
way less than the $100 we will get in 5 years ...
If you would prefer to wait on some progress through clinical trials, you can, but be prepared to pay 10-20X its current market price.
The recent creation of preferred shares will go a long way to preventing a hostile takeover at prices that do not reflect the value of the company's science.
What are the preferred shares going for these days? Not sure if I myself can buy those and I'd prefer to (pun intended).
Looks like a non-event. No surprise there.
Yes, if you wait until clinical trials, the stock price might be higher, but I've done a lot of DD on this one and I can't find any kind of timetable to begin clinical trials, let alone complete them.
This is what we call vaporware.
Maybe that's why the stock price goes nowhere despite all of these news announcements.
NNVC NEEDS TO GET TO A BETTER EXCHANGE. ISNT THE AMEX A NOTCH ABOVE THE OTC.BB
Allan did you see this one : http://translate.google.com/translate?js=n&prev=_t&hl=en&ie=UTF-8&u=http%3A%2F%2Fwww.bosa.co.kr%2Fumap%2Fsub.asp%3Fnews_pk%3D136721&sl=ko&tl=en&history_state0=
"Vaporware" sounds about right, if you are an ignoramus. They are moving forward with everything and in a timely manner.
When they get some early-stage human trials this stock will be already flying off the shelves.
Allan,
I believe this company has great potential, however short term it has been disappointing.
Do you see nay reason for this lack of performance?
Thanks,
Harvey B.
Allan,
I am a believer of this company long term as you are. However, its performance in the last couple of weeks has been surprisingly weak.
Any comments?
Thanks,
Harvey B.
Harvey,
I believe that this company is for real, that it will be front page news, eventually and within five years every 10K shares of NNVC will be worth $1M.
That is my operational premise and it leaves day to day fluctuations in the dust.
Post a Comment